DK1007006T3 - Formulering af cefadroxilmonohydrattablet - Google Patents

Formulering af cefadroxilmonohydrattablet

Info

Publication number
DK1007006T3
DK1007006T3 DK98911832T DK98911832T DK1007006T3 DK 1007006 T3 DK1007006 T3 DK 1007006T3 DK 98911832 T DK98911832 T DK 98911832T DK 98911832 T DK98911832 T DK 98911832T DK 1007006 T3 DK1007006 T3 DK 1007006T3
Authority
DK
Denmark
Prior art keywords
formulation
cefadroxil monohydrate
tablet
monohydrate tablet
cefadroxil
Prior art date
Application number
DK98911832T
Other languages
English (en)
Inventor
Jean Paul Louis Auguste Remon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1007006T3 publication Critical patent/DK1007006T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK98911832T 1997-04-17 1998-03-19 Formulering af cefadroxilmonohydrattablet DK1007006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4414097P 1997-04-17 1997-04-17
PCT/US1998/005412 WO1998046213A1 (en) 1997-04-17 1998-03-19 Cefadroxil monohydrate tablet formulation

Publications (1)

Publication Number Publication Date
DK1007006T3 true DK1007006T3 (da) 2003-09-29

Family

ID=21930720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911832T DK1007006T3 (da) 1997-04-17 1998-03-19 Formulering af cefadroxilmonohydrattablet

Country Status (11)

Country Link
US (1) US6080427A (da)
EP (1) EP1007006B1 (da)
JP (1) JP2002514212A (da)
AT (1) ATE243504T1 (da)
AU (1) AU729437B2 (da)
CA (1) CA2286079A1 (da)
DE (1) DE69815856T2 (da)
DK (1) DK1007006T3 (da)
ES (1) ES2201465T3 (da)
PT (1) PT1007006E (da)
WO (1) WO1998046213A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
IL158390A0 (en) * 2001-05-01 2004-05-12 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
EP1293251A1 (en) * 2001-09-14 2003-03-19 Holland Sweetener Company V.o.F. Process for the production of alpha-L-aspartyl-l-phenylalanine methyl ester powder
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
WO2004016251A1 (en) * 2002-08-16 2004-02-26 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004016250A1 (en) * 2002-08-19 2004-02-26 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
CN1311830C (zh) * 2004-02-27 2007-04-25 石药集团中奇制药技术（石家庄）有限公司 头孢羟氨苄口腔崩解片及其制备方法
JP2007536378A (ja) * 2004-05-10 2007-12-13 ルピン・リミテッド 生体利用性が強化されている新規セフィキシム医薬製剤
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN104800177B (zh) * 2015-05-12 2018-01-16 湖南科伦制药有限公司 一种头孢羟氨苄片及其制备方法
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
CN111388432A (zh) * 2020-03-19 2020-07-10 潍坊富邦药业有限公司 一种宠物用头孢羟氨苄片及其制备方法
CN113908134B (zh) * 2021-12-03 2023-10-27 陕西恒诚制药有限公司 一种头孢羟氨苄分散包衣片的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3584114A (en) * 1968-05-22 1971-06-08 Hoffmann La Roche Free-flowing powders
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3873694A (en) * 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5256440A (en) * 1992-06-22 1993-10-26 Merck & Co., Inc. Process for producing a tablet core aperture
DK0801559T3 (da) * 1995-02-08 2002-06-17 Yamanouchi Europ Bv Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum

Also Published As

Publication number Publication date
DE69815856T2 (de) 2004-05-06
DE69815856D1 (de) 2003-07-31
WO1998046213A1 (en) 1998-10-22
AU6569798A (en) 1998-11-11
ES2201465T3 (es) 2004-03-16
CA2286079A1 (en) 1998-10-22
PT1007006E (pt) 2003-10-31
US6080427A (en) 2000-06-27
EP1007006A1 (en) 2000-06-14
EP1007006B1 (en) 2003-06-25
EP1007006A4 (en) 2001-08-16
ATE243504T1 (de) 2003-07-15
AU729437B2 (en) 2001-02-01
JP2002514212A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
ATE243504T1 (de) Cefadroxilmonohydrat tablettenformulierung
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
PL370292A1 (en) Formulations for oral administration of active compounds
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
MXPA03007712A (es) Sales farmaceuticas.
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
GB9808796D0 (en) Antithrombotic agents
WO2000078294A3 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
WO2005007137A8 (de) Ambroxolhaltige tabletten
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
DK1292303T3 (da) Stabil farmaceutisk formulering omfattende torsemidmodifikation II
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung